Tempus AI’s olivia app allows patients to consolidate healthcare data onto a single platform and gain insights using AI.
Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...
Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding even ...
The following is a summary of “Factors associated with the detection of atrial fibrillation in patients with embolic stroke ...
For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...
That test could help identify patients at greatest risk for potentially deadly cardiac problems such as coronary artery disease, atrial fibrillation (irregular heartbeat) and heart failure, and ...